Products & Services · Sales to Customers
Abiomed — Sales to Customers
Johnson & Johnson Abiomed — Sales to Customers remained flat by 0.0% to $437.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 17.0%, from $374.00M to $437.75M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market adoption and successful commercialization of heart recovery technologies, while a decrease may signal market saturation or competitive pressure.
Detailed definition
This metric represents the total revenue generated from the sale of cardiovascular medical technology products within th...
Peer comparison
Comparable to revenue metrics for specialized medical device divisions or acquired cardiovascular technology segments at peer healthcare companies.
Metric ID:
jnj_segment_abiomed_sales_to_customersHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $31.00M | $1.31B | $1.50B | $1.75B |
| YoY Change | — | — | >999% | +14.5% | +17.0% |
Range$0.00 – $1.75B
Avg YoY Growth>999%
Median YoY Growth+17.0%
Current Streak3+ years growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's abiomed — sales to customers?
- Johnson & Johnson (JNJ) reported abiomed — sales to customers of $437.75M in Q4 2025.
- How has Johnson & Johnson's abiomed — sales to customers changed year-over-year?
- Johnson & Johnson's abiomed — sales to customers increased by 17.0% year-over-year, from $374.00M to $437.75M.
- What does abiomed — sales to customers mean?
- The total revenue earned from selling Abiomed cardiovascular medical products to customers.